The Freedman laboratory at Dana-Farber Cancer Institute and Harvard Medical School studies how the noncoding genome contributes to cancer pathogenesis and progression. Our work is characterized by asking questions of biological and clinical significance and deploying the appropriate tools to rigorously test these hypotheses. We use a variety of molecular biology, statistical, genomic, and epigenomic approaches to understand cancer. If required, we develop novel technology. Our research is highly collaborative and includes laboratory investigators, clinical investigators, and computational biologists. Located in Boston and the surrounding communities, Dana-Farber Cancer Institute is a leader in life changing breakthroughs in cancer research and patient care. We are uni